TNFRSF8 and peripheral T-cell lymphoma, not otherwise specified: Recently, brentuximab vedotin was also approved for frontline treatment of systemic ALCL and other CD30-expressing peripheral T-cell lymphomas after showing an OS benefit when combined with chemotherapy over chemotherapy alone for peripheral T-cell lymphomas [52,57].